Trial NCT00485589

View at ClinicalTrials.gov 
Org. Study IDs: ACT3984g
Secondary IDs: WA20497

Last trial update was posted on 2020-11-03

MeSH Interventions

Methotrexate Ocrelizumab

MeSH Conditions

Arthritis Arthritis, Rheumatoid

Other Conditions

Rheumatoid Arthritis

Stopping Reasons

Based on analysis of results and consideration of available treatments, the overall benefit to risk profile of ocrelizumab was not favorable in RA.

Limitations And Caveats

The study was terminated prematurely by the sponsors before all patients could reach the time point for primary analysis at Week 104. No patient received any further infusions of study medication.

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID